Search

SC12267

SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. … Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.

Sodium oxybate

[A251430] Due to its physiological effects, sodium oxybate is associated with a risk for substance misuse and abuse. … [A18723] For safety reasons, sodium oxybate is a controlled substance only available through a restricted program in approved countries.

Lactose

It is used in pharmacy for tablets, in medicine as a nutrient, and in industry.

1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

The product was meant to compensate for alveolar surfactant deficiency and reduce to likelihood of alveolar collapse leading to acute respiratory collapse.

Apramycin

It is not approved for use in humans.

L-Acetylleucine

DL-) form has been available in France since 1957 for the treatment of vertigo. … [A264439] In September 2024, the FDA approved levacetylleucine for the treatment of select patients with NPC.[L51444]

NXN-188

NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

Noscapine

Trofinetide

, making trofinetide the first and only treatment approved for Rett syndrome in the European Union. … [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive

NV-52

NV-52 is an investigational synthetic flavonoid thromboxane synthase (TXS) inhibitor developed for the maintenance of remission in inflammatory bowel disease.